MARKET

EBS

EBS

Emergent Biosolutions Inc
NYSE
12.00
+0.19
+1.61%
After Hours: 12.55 +0.55 +4.58% 17:37 12/02 EST
OPEN
11.65
PREV CLOSE
11.81
HIGH
12.01
LOW
11.47
VOLUME
937.70K
TURNOVER
0
52 WEEK HIGH
52.28
52 WEEK LOW
11.34
MARKET CAP
598.66M
P/E (TTM)
14.63
1D
5D
1M
3M
1Y
5Y
Opioid reversal agent naloxone approvable for OTC use – FDA
Seekingalpha · 11/15 18:37
EXCLUSIVE: SAB Biotherapeutics Posts Wider Quarterly Loss, Cash Runway Expected Into Mid-2023
Benzinga · 11/15 13:10
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Benzinga · 11/15 10:19
Indivior To Pay Over 100% Premium To Buy Opioid Focused Player Opiant Pharmaceuticals
Benzinga · 11/14 12:47
Emergent gets research award from US DoD for chikungunya vaccine study
Seekingalpha · 11/14 12:36
BRIEF-Emergent Biosolutions Receives Department Of Defense Award To Evaluate Chikungunya Vaccine Candidate
Reuters · 11/14 11:54
Emergent BioSolutions Receives Department Of Defense Award To Evaluate Chikungunya Vaccine Candidate In Post-Approval Field Efficacy Study Using Model-Guided Approach
Benzinga · 11/14 11:36
Emergent BioSolutions lowers revenue guidance amid uncertainty over government's vaccine purchases
The Gaithersburg company is a longtime supplier to the federal government's Strategic National Stockpile.
American City Business Journals · 11/10 20:26
More
About EBS
Emergent BioSolutions, Inc. is a life sciences company focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats (PHTs). The Company is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. It provides solutions for PHTs through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. It offers TEMBEXA (brincidofovir) an antiviral for the treatment of smallpox in all age groups, including adults, and for patients who have difficulty swallowing.

Webull offers kinds of Emergent Biosolutions Inc stock information, including NYSE:EBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EBS stock methods without spending real money on the virtual paper trading platform.